会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • SINGLE LAYER FUEL TANK
    • 单层燃油箱
    • US20110000127A1
    • 2011-01-06
    • US12496913
    • 2009-07-02
    • Zhenguo LiuStephen J. HanleyFrank Aadahl
    • Zhenguo LiuStephen J. HanleyFrank Aadahl
    • C10L1/182B32B1/02B32B27/34
    • B60K15/03177Y10T428/1352Y10T428/1397Y10T428/31725
    • A single layer fuel tank includes a polyamide component, an impact modifier, and a binding filler. The polyamide component has a polyamide selected from the group of polyamide 6, polyamide 6/6, polyamide 6/66, and combinations thereof. The polyamide component also includes up to 5 parts by weight of polyamide oligomers per 100 parts by weight of the polyamide component. The impact modifier is an organic copolymer and is present in an amount of up to 30 parts by weight per 100 parts by weight of the fuel tank. The binding filler is not covalently bonded to the polyamide and includes at least one of a silica and a cyclodextrin. In addition, the binding filler is present in an amount of up to 10 parts by weight per 100 parts by weight of the fuel tank.
    • 单层燃料箱包括聚酰胺组分,抗冲改性剂和粘结填料。 聚酰胺组分具有选自聚酰胺6,聚酰胺6/6,聚酰胺6/66及其组合的聚酰胺。 聚酰胺组分还包含每100重量份聚酰胺组分最多5重量份的聚酰胺低聚物。 抗冲改性剂是一种有机共聚物,相对于燃料箱100重量份,其含量可高达30重量份。 结合填料不与聚酰胺共价键合,并且包括二氧化硅和环糊精中的至少一种。 此外,结合填料的存在量为每100重量份燃料箱高达10重量份。
    • 2. 发明授权
    • Single layer fuel tank
    • 单层燃油箱
    • US08092884B2
    • 2012-01-10
    • US12496913
    • 2009-07-02
    • Zhenguo LiuStephen J. HanleyFrank Aadahl
    • Zhenguo LiuStephen J. HanleyFrank Aadahl
    • B29D22/00B29D23/00B32B1/08
    • B60K15/03177Y10T428/1352Y10T428/1397Y10T428/31725
    • A single layer fuel tank includes a polyamide component, an impact modifier, and a binding filler. The polyamide component has a polyamide selected from the group of polyamide 6, polyamide 6/6, polyamide 6/66, and combinations thereof. The polyamide component also includes up to 5 parts by weight of polyamide oligomers per 100 parts by weight of the polyamide component. The impact modifier is an organic copolymer and is present in an amount of up to 30 parts by weight per 100 parts by weight of the fuel tank. The binding filler is not covalently bonded to the polyamide and includes at least one of a silica and a cyclodextrin. In addition, the binding filler is present in an amount of up to 10 parts by weight per 100 parts by weight of the fuel tank.
    • 单层燃料箱包括聚酰胺组分,抗冲改性剂和粘结填料。 聚酰胺组分具有选自聚酰胺6,聚酰胺6/6,聚酰胺6/66及其组合的聚酰胺。 聚酰胺组分还包含每100重量份聚酰胺组分最多5重量份的聚酰胺低聚物。 抗冲改性剂是一种有机共聚物,相对于燃料箱100重量份,其含量可高达30重量份。 结合填料不与聚酰胺共价键合,并且包括二氧化硅和环糊精中的至少一种。 此外,结合填料的存在量为每100重量份燃料箱高达10重量份。
    • 5. 发明授权
    • Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
    • 可生物降解聚合物包封的药物组合物及其制备方法
    • US06455526B1
    • 2002-09-24
    • US09454555
    • 1999-12-07
    • Rachel S. KohnStephen J. HanleyStephen J. Comiskey
    • Rachel S. KohnStephen J. HanleyStephen J. Comiskey
    • A61K31495
    • A61K31/50A61K9/1647A61K9/1694A61K31/495
    • A new class of biodegradable pharmaceutical compositions useful as sustained release medicamentous compositions, including methods of making and methods of using these compositions, are described and claimed. The method of making these compositions include the steps of: a) dry mixing of a pharmaceutically active molecule with a biodegradable polymer; b) melt extruding the mixture to form a solid solution of the active molecule in the polymer; and c) pulverizing the solid solution to form microparticles such that they can be formed into injectable formulations. Preferred embodiments include pharmaceutical compositions of polylactide-co-glycolide and (+)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (active ingredient) and a method for its formation. These compositions release the active ingredient at a steady rate over a period of days to weeks. The active ingredient antagonizes the effects of serotonin at the 5HT2A receptor and are useful in treating various conditions such as, for example, psychoses including schizophrenia, obsessive compulsive disorder, sleep disorder, depression, anorexia, anxiety, drug addiction and bipolar disorders.
    • 描述和要求保护的一类新的可生物降解的药物组合物,其用作缓释药物组合物,包括制备方法和使用这些组合物的方法。 制备这些组合物的方法包括以下步骤:a)将药物活性分子与可生物降解的聚合物干混; b)熔融挤出混合物以形成聚合物中活性分子的固溶体; 和c)粉碎固溶体以形成微粒,使得它们可以形成可注射制剂。 优选的实施方案包括聚丙交酯 - 共 - 乙交酯和(+) - α-(2,3-二甲氧基苯基)-1- [2-(4-氟苯基)乙基] -4-哌啶甲醇(活性成分)的药物组合物和 其形成。 这些组合物在几天到数周的时间内以稳定的速率释放活性成分。 活性成分拮抗5-羟色胺在5HT2A受体上的作用,可用于治疗各种病症,例如精神病,包括精神分裂症,强迫症,睡眠障碍,抑郁症,厌食症,焦虑症,药物成瘾和双相性精神障碍。